Highlights MiNK Therapeutics, Inc.

Equities

INKT

US6036931029

Real-time Estimate Cboe BZX Other stock markets 20:26:37 14/05/2024 BST			5-day change	1st Jan Change
1.15 ^USD	+17.37%		+23.64%	+7.48%

05-13	Wall Street Set to Open Higher Monday as Investors Look Toward Key Inflation Figures	MT
05-13	MiNK Therapeutics, Inc. announced that it expects to receive $5.8 million in funding	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MiNK Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-21	CI
MiNK Therapeutics, Inc. Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024	03-06	CI
MiNK Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study for agenT-797 in Second Line Gastroesophageal Cancer	02-14	CI
Mink Therapeutics' Agent-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications	02-06	CI
MiNK?s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene	01-30	CI
MiNK Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
MiNK Therapeutics, Inc. Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023	11-03	CI
MiNK Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
MiNK Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23	CI
Agenus Inc. spin-off 14.5% stake in MiNK Therapeutics, Inc. for $9.1 million.	30/04/23	CI
Mink Therapeutics, Inc. Presents Clinical Data At Sitc 2022 Showcasing Inkt Cell Therapy Pipeline	10/11/22	CI
MiNK Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	03/11/22	CI
MiNK Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	09/08/22	CI
MiNK Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	10/05/22	CI
MiNK Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	18/03/22	CI
MiNK Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results	18/03/22	GL
MiNK Therapeutics Announces Patients Dosed with Agent-797 iNKT Cell Therapy in Solid Tumor Cancers	03/03/22	CI
Mink Therapeutics : Closes IPO	19/10/21	MT
MiNK Therapeutics : Prices IPO at $12 Per Share	15/10/21	MT
MiNK Therapeutics, Inc. has completed an IPO in the amount of $40.000008 million.	14/10/21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights MiNK Therapeutics, Inc.

Equities

INKT

US6036931029

Highlights

Filters